APREPITANT (aprepitant) by R-Pharm US is neurokinin 1 antagonists [moa]. Approved for substance p/neurokinin-1 receptor antagonist [epc]. First approved in 2020.
Drug data last refreshed 29m ago
Neurokinin 1 Antagonists
Substance P/Neurokinin-1 Receptor Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Aprepitant to Improve Same Day Discharge for TKA
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Worked on APREPITANT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moR-Pharm US is hiring 1 role related to this product